TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities with various academic and clinical research organizations, including the transfer of its intellectual property assets to its recently formed wholly-owned…


Previous articleMindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
Next articlePTSF67 – Psilocybin, Power, and Patents